BAX — Baxter International Inc. stock price, charts and financials

NYSE·Healthcare·Medical - Instruments & Supplies·USA

Latest market price

28.10

+1.94+7.42%

Overview Short InterestFilings

BAXQT75Baxter International Inc.·NYSE

Overview Short InterestFilings

28.10+7.42%

News

Up 7.4% — Baxter International: The Gains Can Continue, But Should Slow (seekingalpha.com).

Medium confidence

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

COO+2.64%$74.23 SOLV+3.08%$88.07 AVTR-0.80%$13.67 ATR+2.10%$136.77 RGEN+4.29%$147.06 WST+2.05%$347.94 TFX+2.19%$139.70 BLCO-0.83%$16.77

Snapshot

Index	S&P 500	P/E	-	EPS (ttm)	-2.10	Insider Own	0.76%	Shs Outstand	516.47M	Perf Week	16.79%

Market Cap	13.51B	Forward P/E	13.00	EPS next Y	2.01	Insider Trans	0.00%	Shs Float	511.54M	Perf Month	20.61%

Enterprise Value	21.03B	PEG	0.16	EPS next Q	-	Inst Own	-	Short Float	7.20%	Perf Quarter	48.81%

Income	-1.06B	P/S	1.18	EPS this Y	194.20%	Inst Trans	-	Short Ratio	5.21	Perf Half Y	32.59%

Sales	11.47B	P/B	2.18	EPS next Y	1.76%	ROA	-5.37%	Short Interest	36.84M	Perf YTD	36.89%

Book/sh	-	P/C	16.47	EPS next 5Y	4.08%	ROE	-16.60%	52W High	32.22 -12.80%	Perf Year	-6.74%

Cash/sh	-	P/FCF	42.62	EPS past 3/5Y	-	ROIC	-1.61%	52W Low	16.90 66.31%	Perf 3Y	-46.56%

Dividend Est.	0.04 (0.14%)	EV/EBITDA	28.04	Sales past 3/5Y	3.79% -0.75%	Gross Margin	30.08%	Volatility	6.28% 3.91%	Perf 5Y	-67.76%

Dividend TTM	0.20 (0.71%)	EV/Sales	1.83	EPS Y/Y TTM	-65.35%	Oper. Margin	-2.39%	ATR (14)	1.14	Perf 10Y	-43.25%

Dividend Ex-Date	Aug 28, 2026	Quick Ratio	1.32	Sales Y/Y TTM	6.43%	Profit Margin	-9.27%	RSI (14)	70.84	Recom	2.61

Dividend Gr. 3/5Y	-23.25% -11.45%	Current Ratio	1.95	EPS Q/Q	-34.55%	SMA20	13.63%	Beta	0.58	Target Price	23.43

Payout	-17.31%	Debt/Eq	1.56	Sales Q/Q	2.90%	SMA50	23.15%	Rel Volume	1.29	Prev Close	26.16

Employees	37,500	LT Debt/Eq	1.63	Earnings	Oct 29	SMA200	33.62%	Avg Volume	6.90M	Price	28.10

IPO Date	Oct 27, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.77% 3.27%	Net Debt/EBITDA	10.02	Volume	8,913,470	Change	7.42%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-31-26	Reiterated	Stifel Nicolaus	Hold	$24 → $28
Jul-31-26	Upgrade	Citigroup	Sell → Neutral
Jul-28-26	Reiterated	Stifel Nicolaus	Hold	$19 → $24
Jul-28-26	Reiterated	UBS	Neutral	$19 → $25
Jul-15-26	Reiterated	Goldman Sachs	Neutral	$17 → $21
Jul-06-26	Reiterated	Evercore ISI Group	Outperform	$23 → $24
May-28-26	Downgrade	Citigroup	Neutral → Sell
May-04-26	Reiterated	Barclays	Overweight	$25 → $27
Feb-17-26	Reiterated	Goldman Sachs	Neutral	$23 → $17
Feb-16-26	Reiterated	UBS	Neutral	$21 → $19

Latest News

Today

Today03:06AM

Baxter International: The Gains Can Continue, But Should Slowseekingalpha.com

Jul-30-26

Jul-30-2607:29PM

Baxter International Inc (BAX) Shares Surge 8.0% -- What GF Score of 64 Tells Investorsgurufocus.com

01:06PM

BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contractzacks.com

12:23PM

Baxter International Inc. (BAX) Q2 2026 Earnings Call Transcriptseekingalpha.com

11:33AM

Baxter Jumps After Q2 Beat, Boosted 2026 Guidance Reflects Turnaround Progressbenzinga.com

11:02AM

Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com

09:36AM

Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimateszacks.com

07:47AM

Baxter raises annual profit forecast on strong demand for IV solutionsreuters.com

07:15AM

Baxter Reports Second-Quarter 2026 Resultsbusinesswire.com

Jul-29-26

Jul-29-2611:56AM

Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?zacks.com

Jul-27-26

Jul-27-2610:45PM

3 Unprofitable Stocks That Fall ShortYahoo

07:53PM

Baxter International Inc (BAX) Shares Surge 4.2% -- What GF Score of 60 Tells Investorsgurufocus.com

Jul-24-26

Jul-24-2606:57PM

A Look at Baxter International Inc (BAX) After 3.4% Gain -- GF Value $34.41 vs Price $22.40gurufocus.com

12:25PM

Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?zacks.com

Jul-23-26

Jul-23-2611:02AM

Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Declinezacks.com

Company

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	11,470	11,244	10,636	10,360	10,057	12,146	11,673	11,362	11,099
Cost of Goods Sold Incl. D&A	8,020	7,865	6,652	6,210	6,508	7,426	7,086	6,601	6,340
Gross Profit	3,450	3,379	3,984	4,150	3,549	4,720	4,587	4,761	4,759
Selling, General and Administrative Excl. Other	2,932	2,890	2,967	2,953	3,097	2,845	2,469	2,535	2,620
Research and Development	512	518	590	518	450	531	521	595	654
Other Operating Expense	280	279	413	-28	2,847	-6	-19	-141	-99
Operating Income	-274	-308	14	707	-2,845	1,350	1,616	1,772	1,584
Interest Expense	292	290	408	508	413	207	153	111	93
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	83	93	105	43	10	-27	-171	-691	126
Net Income Before Taxes	-483	-505	-289	242	-3,248	1,116	1,292	970	1,617
Income Taxes	485	395	37	61	-135	83	182	-41	65
Consolidated Net Income	-1,063	-957	-649	2,656	-2,433	1,284	1,102	1,001	1,546
Net Income From Continuing Operations	-968	-900	-326	181	-3,113	1,033	1,110	1,011	1,552
Net Income	-1,063	-957	-649	2,656	-2,433	1,284	1,102	1,001	1,546
EPS (Recurring)	-2.04	-1.75	-1.27	5.25	-4.83	2.56	2.17	1.97	3.04
EPS (Basic, Before Extraordinaries)	-2.04	-1.75	-1.27	5.25	-4.83	2.56	2.17	1.97	3.04
EPS (Diluted)	-2.04	-1.75	-1.27	5.23	-4.83	2.53	2.13	1.93	2.97
EBITDA	750	766	1,116	1,734	-1,763	2,190	2,268	1,870	2,481
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	7.39	—	33.93	37.67	43.33	22.16
Price To Sales Ratio	1.27	0.87	1.40	1.89	2.55	3.55	3.50	3.75	3.17
Gross Margin	30.08	30.05	37.46	40.06	35.29	38.86	39.30	41.90	42.88
Operating Margin	-2.39	-2.74	0.13	6.82	-28.29	11.11	13.84	15.60	14.27
Net Margin	-9.27	-8.51	-6.10	25.64	-24.19	10.57	9.44	8.81	13.93
Shares Outstanding	517	513	510	506	504	502	509	509	534
Market Capitalization	14,528	9,803	14,872	19,562	25,689	43,092	40,842	42,563	35,148
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mason Jeanne K	EVP, Chief HR Officer	Mar 01 '24	Option Exercise	37.17	64,488	2,397,019	206,778	Mar 05
Mason Jeanne K	EVP, Chief HR Officer	Mar 01 '24	Sale	40.61	64,488	2,618,858	142,290	Mar 05
STROUCKEN ALBERT P L	Director	Mar 20 '23	Option Exercise	36.93	3,930	145,135	40,765	Mar 22
STROUCKEN ALBERT P L	Director	Mar 20 '23	Sale	37.52	3,930	147,454	36,835	Mar 22
Kunzler Jacqueline	SVP, Chief Quality Officer	Feb 21 '23	Option Exercise	37.82	4,163	157,445	20,538	Feb 23
Kunzler Jacqueline	SVP, Chief Quality Officer	Feb 21 '23	Sale	40.50	3,813	154,427	16,725	Feb 23
Mason Jeanne K	SVP, Human Resources	Jan 17 '23	Option Exercise	18.91	118,954	2,249,420	185,708	Jan 19
Mason Jeanne K	SVP, Human Resources	Jan 17 '23	Sale	44.70	59,477	2,658,622	126,231	Jan 19
HELLMAN PETER S	Director	Apr 05 '22	Sale	76.02	4,020	305,594	27,629	Apr 07
STROUCKEN ALBERT P L	Director	Apr 05 '22	Option Exercise	29.52	4,020	118,670	38,147	Apr 07
STROUCKEN ALBERT P L	Director	Apr 05 '22	Sale	76.02	4,020	305,612	34,127	Apr 07
HELLMAN PETER S	director:	Apr 05 '22	Option Exercise	29.52	4,020	118,670	31,649	Apr 07
FORSYTH JOHN D	director:	Apr 01 '22	Option Exercise	0.00	1,005	0	1,005	Apr 05
FORSYTH JOHN D	director:	Apr 01 '22	Sale	77.68	1,005	78,068	27,029	Apr 05
FORSYTH JOHN D	Director	Mar 01 '22	Option Exercise	29.52	1,005	29,668	28,034	Mar 03

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.